Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Phillips, Robert S ^a   Friend, Amanda J ^b   Gibson, Faith ^c   Houghton, Elizabeth ^d   Gopaul, Shireen ^e   Craig, Jean V ^f   Pizer, Barry ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b LEEDS COMMUNITY HEALTHCARE NHS TRUST   (United Kingdom)

^c LONDON SOUTH BANK UNIVERSITY   (United Kingdom)

^d ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; CANNABINOID; CHLORPROMAZINE; CYCLIZINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; GRANISETRON; LEVOMEPROMAZINE; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MIDAZOLAM; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; STEROID; TROPISETRON; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; ANOREXIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILDHOOD CANCER; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEVER; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; LEG PAIN; LEUKOPENIA; MOOD DISORDER; MYALGIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PRURITUS; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTIGO; XEROSTOMIA; ADOLESCENT; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHILD; COMBINATION DRUG THERAPY; META ANALYSIS; NAUSEA; NEOPLASMS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; NAUSEA; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN ANTAGONISTS; VOMITING;

EID: 84969522946     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007786.pub3     Document Type: Review

References (133)

1. Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. Journal of Pediatric Hematology/Oncology 1995;17(2):145-50.
2. Basade M, Kulkarni SS, Dhar AK, Sastry PS, Saikia B, Advani SH. Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy. Indian Pediatrics 1996;33(4):321-3.
3. Berrak SG, Ozdemir N, Bakirci N, Turkkan E, Canpolat C, Beker B, et al. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Supportive Care in Cancer 2007;15(10):1163-8.
4. Brock P, Brichard B, Rechnitzer C, Langeveld NE, Lanning M, Soderhall S, et al. An increased loading dose of ondansetron: a north European, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2. European Journal of Cancer 1996;32A(10):1744-8.
5. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987;79(6):946-52.
6. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Archives of Disease in Childhood 1986;61(5):502-5.
7. Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Archives of Disease in Childhood 1995;73(3):243-5.
8. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2:657-9.
9. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2(12):657-9.
10. Emir S, Erturgut P, Vidinlisan S. Comparison of granisetron plus dexamethasone versus an antiemetic cocktail containing midazolam and diphenhydramine for chemotherapy induced nausea and vomiting in children. Indian Journal of Medical and Paediatric Oncology 2013;34(4):270-3.
11. Graham-Pole J, Weare J, Engel S, Gardner R, Mehta P, Gross S. Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine. Journal of Clinical Oncology 1986;4(7):1110-3.
12. Hahlen K, Quintana E, Pinkerton CR, Cedar E. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. Journal of Pediatrics 1995;126(2):309-13.
13. Hirota T, Honjo T, Kuroda R, Saeki K, Katano N, Sakakibara Y, et al. Antiemetic efficacy of granisetron in pediatric cancer treatment - (2). Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1993;20(15):2369-73.
14. Jaing T-H, Tsay P-K, Hung I-J, Yang C-P, Hu W-Y. Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatric Hematology & Oncology 2004;21(3):227-35.
15. Komada Y, Matsuyama T, Takao A, Hongo T, Nishimura Y, Horibe K, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. European Journal of Cancer 1999;35(7):1095-101.
16. Kurucu N, Durmaz M. Effect of hydroxyzine in controlling acute chemotherapy-induced vomiting in children: a randomised trial. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi 2012;22(2):99-106.
17. Mabro M, Cohn R, Zanesco L, Madon E, Hahlen K, Margueritte G, et al. Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses. Bulletin du Cancer 2000;87(3):259-64.
18. Marshall G, Kerr S, Vowels M, O'Gorman-Hughes D, White L. Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. Journal of Pediatrics 1989;115(1):156-60.
19. Mehta P, Gross S, Graham-Pole J, Gardner R. Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children. Journal of Pediatrics 1986;108(5 Pt 1):774-6.
20. Mehta NH, Reed CM, Kuhlman C, Weinstein HJ, Parsons SK. Controlling conditioning-related emesis in children undergoing bone marrow transplantation. Oncology Nursing Forum 1997;24(9):1539-44.
21. Nagel K, Willan AR, Lappan J, Korz L, Buckley N, Barr RD. Pediatric Oncology Sedation Trial (POST): a double-blind randomized study. Pediatric Blood and Cancer 2008;51:634-8.
22. Noguera D, Gómez R, Marcano A. 5-hydroxytriptamine type 3 receptor antagonists in the prevention of vomiting by cytostatics drugs in children [Antagonistas de receptores 5-hidroxitriptamina tipo 3 en la prevención de emesis por citostáticos en niños]. Salus Militiae 2001;26(1):71-6.
23. Orchard PJ, Rogosheske J, Burns L, Rydholm N, Larson H, DeFor TE, et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biology of Blood & Marrow Transplantation 1999;5(6):386-93.
24. Parker RI, Prakash D, Mahan RA, Giugliano DM, Atlas MP. Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. Journal of Pediatric Hematology/Oncology 2001;23(9):578-81.
25. Safonova SA, Gershanovich ML, Punanov IuA, Kolygin BA. Evaluation of the anti-emetic effectiveness of two drug formulations of ondansetron in combined chemotherapy for children with malignant tumors. Voprosy Onkologii 1999;45(4):424-8.
26. Sandoval C, Corbi D, Strobino B, Ozkaynak MF, Tugal O, Jayabose S. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Investigation 1999;17(5):309-13.
27. Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Marquez H, Villasis-Keever MA, del Angel VW, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Archives of Medical Research 2008;39:601-6.
28. Shi X, Liu ZM, Zhu XD. Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride. Chinese Journal of Integrated Traditional and Western Medicine 2012;32(4):468-70.
29. Siddique R, Hafiz MG, Rokeya B, Jamal CY, Islam A. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukaemia. Mymensingh Medical Journal 2011;20(4):680-8.
30. Suarez A, Stettler ER, Rey E, Pons G, Simonetta-Chateauneuf C, de Bruijn KM, et al. Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy. European Journal of Cancer 1994;30A(10):1436-41.
31. Swann IL, Thompson EN, Qureshi K. Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting. British Medical Journal 1979;2(6199):1188.
32. Tejedor I, Idoate A, Jimenez M, Sierrasesumaga L, Giraldez J. Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children. Pharmacy World & Science 1999;21(2):60-8.
33. Tsuchida Y, Hayashi Y, Asami K, Yamamoto K, Yokoyama J, Mugishima H, et al. Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. International Journal of Oncology 1999;14(4):673-9.
34. White L, Daly SA, McKenna CJ, Zhestkova N, Leal C, Breatnach F, et al. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatric Hematology & Oncology 2000;17(6):445-55.
35. Aksoylar S, Akman SA, Ozgenc F, Kansoy S. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatric Hematology & Oncology 2001;18(6):397-406.
36. Alavi JB, Torri S, Glover D, Hurwitz S, Glick JH. High-dose oral metoclopramide. An effective antiemetic agent. American Journal of Clinical Oncology 1985;8(3):260-5.
37. Basch E, Hesketh PJ, Kris MG, Prestrud AA, Temin S, Lyman GH. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Oncology Practice 2011;7(6):395-7.
38. Bauduer F, Coiffier B, Desablens B. Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group. Leukemia & Lymphoma 1999;34(3-4):341-7.
39. Bonaventura A, Freeman S, Stewart J, Ackland S, Hall K, Gebski V. Control of acute and delayed vomiting with lorazepam, dexamethasone and metochlopramide (LDM) versus dexamethasone and ondansetron (DO) following highly emetogenic chemotherapy (meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1999:2299.
40. Brice P, Fiere D, Gastaut JL, Simon-Lejeune C, Carcassonne Y, Tredaniel J, et al. Comparison of the antiemetic effectiveness of high-dose corticosteroids with synacthene in nausea induced by chemotherapy: results of a randomized study. Bulletin du Cancer 1989;76(6):637-42.
41. Corapcioglu F, Sarper N. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer. Pediatric Hematology and Oncology 2005;22(2):103-14.
42. Dana BW, McDermott M, Everts E, Abdulhay G. A randomized trial of high-dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis. American Journal of Clinical Oncology 1987;10(3):253-6.
43. Delgado G, Stefanuto W, Novo NF. Preconous toxicity syndrome due to cancer chemotherapy: therapeutic effects of metoclopramide and corticosteroids compared with placebo [Síndrome da toxidade precoce induzida pela quimioterapia antineoplásica: efeito terapêutico de metoclopramida e corticosteróide versus placebo e proposta de um modelo patogênico]. Acta Oncologica (Brasil) 1983;3(1/3):19-29.
44. Fauser A, Pizzocaro G, Schuller G, Khayat D, Wilkinson P. A double-blind parallel study of intravenous (IV) dolasetron + dexamethasone vs. iv dolasetron alone in preventing fractionated cisplatin emesis (meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1998:abstract 223.
45. Feng FY, Zhang P, He YJ, Li YH, Zhou MZ, Cheng G, et al. Comparison of the selective serotonin antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study. Current Therapeutic Research - Clinical and Experimental 2000;61(12):901-9.
46. Feng FY, Zhang P, He YJ, Li YH, Zhou MZ, Cheng G, et al. Oral formulations of the selective serotonin antagonists ramosetron (intraoral disintegrator formulation) and granisetron hydrochloride (standard tablet) in treating acute chemotherapy-induced emesis, nausea, and anorexia: a multicenter, randomized, single-blind, crossover, comparison study. Current Therapeutic Research - Clinical and Experimental 2002;63(11):725-35.
47. Forni C, Ferrari S, Loro L, Mazzei T, Beghelli C, Biolchini A, et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Supportive Care in Cancer 2000;8(2):131-3.
48. Friedman CJ, Burris HA, Yocom K, Blackburn LM, Gruben D. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist 2000;5(2):136-43.
49. Gagen M, Gochnour D, Young D, Gaginella T, Neidhart J. A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting. Journal of Clinical Oncology 1984;2(6):696-701.
50. Gez E, Ben-Yosef R, Catane R, Brufman G, Biran S. Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study. Oncology 1989;46(3):150-4.
51. Gorena M, Giacaman A, Pastor P. Antiemetic therapy in testis cancer chemotherapy: comparison in cross-over study of ondansetron and metoclopramide [Terapia antiemética en quimioterapia por cáncer testicular: comparación en estudio cross-over de ondansetron y metoclopramida]. Revista Chile Urologica 1996;61(1):72-4.
52. Hatae Y, Takeda T, Nakadate H, Hatayama Y, Kishino T, Ogawa Y. The antiemetic effect and clinical evaluation of metoclopramide alone and combined with betamethasone in children with malignant tumor. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1989;16(11):3639-42.
53. Herrstedt J, Sigsgaard TC, Nielsen HA, Handberg J, Langer SW, Ottesen S, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Supportive Care in Cancer 2007;15(4):417-26.
54. Hirota T, Honjo T, Kuroda R, Saeki K, Katano N, Sakakibara Y, et al. Antiemetic efficacy of granisetron in the treatment of pediatric cancer - (1). Clinical evaluation of granisetron at a dose of 40 micrograms/kg. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1993;20(14):2201-5.
55. Jara C, Hernandez M, Alonso C, Fernandez A, Gamez-Aldarava JL, Mayordomo JI. Dexamethasone with oral granisetron or metoclopramide in preventing chemotherapy-induced delayed emesis. A randomized, double-blind trial (meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1999:abstract 2289.
56. Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology 1994;5(3):253-8.
57. Kearsley JH, Williams AM, Fiumara AM. Antiemetic superiority of lorazepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy. Cancer 1989;64(8):1595-9.
58. Keyhanian S, Taziki O, Saravi MM, Fotokian Z. A randomized comparison of granisetron plus dexamethason with granisetron alone for the control of acute chemotherapy-induced emesis and nausea. International Journal of Hematology-Oncology and Stem Cell Research 2009;3(2):27-30.
59. Koseoglu V, Kurekci AE, Sarici U, Atay AA, Ozcan O. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. European Journal of Pediatrics 1998;157(10):806-10.
60. Luisi FAV, Petrilli AS, Tanaka C, Caran EMM. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Medical Journal 2006;124(2):61-5.
61. Matsuoka S, Okamoto S, Watanabe R, Mori T, Nagayama H, Hamano Y, et al. Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. International Journal of Hematology 2003;77(1):86-90.
62. Nathan PC, Tomlinson G, Dupuis LL, Greenberg ML, Ota S, Bartels U, et al. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Supportive Care in Cancer 2006;14(3):268-76.
63. NCT00429702 . Diphenhydramine, lorazepam, and dexamethasone in treating nausea and vomiting caused by chemotherapy in young patients with newly diagnosed cancer. clinicaltrials.gov/show/NCT00429702 (accessed 15 May 2010).
64. Needles B, Miranda E, Garcia Rodriguez FM, Diaz LB, Spector J, Craig J, et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. Supportive Care in Cancer 1999;7(5):347-53.
65. Onat H, Inanc SE, Saip P, Topuz E. Tropisetron (TRP) in the prevention of emesis associated with 5-day cisplatin-based chemotherapy (CT) in patients (pts) with germ cell tumors (Meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1995:abstract 1760.
66. Pillai AK, Sharma KK, Gupta YK, Bakshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatric Blood and Cancer 2011;56:234-8.
67. Relling MV, Mulhern RK, Fairclough D, Baker D, Pui CH. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. Journal of Pediatrics 1993;123(5):811-6.
68. Roila F, De Angelis V, Cognetti F, Ricci S, Contu A, Nuzzo A, et al. Ondansetron vs granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis (Meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1995:abstract 1721.
69. Roila F, De Angelis V, Contu A, Scagliotti G, Tateo S, Massidda B, et al. Ondansetron (OND) vs metoclopramide (MTC) both combined with dexamethasone (DEX) in the prevention of cisplatin (CDDP)-induced delayed emesis (Meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1996:abstract 1705.
70. Roila F, Ballatori E, Contu A, Tateo S, Ricci S, Ionta MT, et al. Optimal dose of intravenous dexamethasone in the prevention of cisplatin-induced acute emesis: a double blind randomized study. (Meeting abstract). ASCO Conference Abstracts. Chicago: ASCO, 1998:abstract 195.
71. Roila F, Ballatori E, Bosnjak S, Fava S, Nuzzo A, Contu A, et al. Dexamethasone (DEX) alone or combined with ondansetron (OND) in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (MEC). Proceedings of the American Society of Clinical Oncology 2000;19:(abstr 2358).
72. Stiakaki E, Savvas S, Lydaki E, Bolonaki I, Kouvidi E, Dimitriou H, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatric Hematology & Oncology 1999;16(2):101-8.
73. Sumer T, Abu-Melha A, Maqbool G, Al-Mulhim I. Dexamethasone as an antiemetic in children receiving cis-platinum. American Journal of Pediatric Hematology/Oncology 1988;10(2):126-8.
74. Tian W, Wang Z, Zhou J, Zhang S, Wang J, Chen Q, et al. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Medical Oncology 2011;28:71-8.
75. Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, et al. Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial. International Journal of Clinical Oncology 2009;14:337-43.
76. Yalcin S, Tekuzman G, Baltali E, Ozisik Y, Barista I. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. American Journal of Clinical Oncology: Cancer Clinical Trials 1999;22(1):94-6.
77. Yonemura M, Katsumata N, Hashimoto H, Satake S, Kaneko M, Kobayashi Y, et al. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Japanese Journal of Clinical Oncology 2009;39(7):443-8.
78. Gómez MH, Mas LL, Vallejos SC. Tropisetron with dexamethasone in the control of nausea and vomiting in emetogenic chemotherapy [Tropisetron mas dexametasona en el control de náuseas y vómitos en pacientes con quimioterapia emetizante]. Acta Cancerologica 1995;25(2):55-60.
79. Xu B, Zhou J, Zhou A. Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 1997;19(5):358-61.
80. Zeng W, Zhou J, Zhang P. The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting - a randomized clinical trial. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 1995;17(4):294-7.
81. Antonarakis ES, Evans JL, Heard GF, Noonan LM, Pizer BL, Hain RDW. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?. Pediatric Blood and Cancer 2004;43(6):651-8.
82. Antonarakis ES, Hain RDW. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. Archives of Disease in Childhood 2004;89(9):877-80.
83. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331(7521):897-900.
84. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 2009;373(9665):746-58.
85. Cotanch P, Hockenberry M, Herman S. Self-hypnosis as antiemetic therapy in children receiving chemotherapy. Oncology Nursing Forum 1985;12(4):41-6.
86. Coyne I. Children's experiences of hospitalization. Journal of Child Health Care: For Professionals Working with Children in the Hospital and Community 2006;10(4):326-36.
87. Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatric Drugs 2001;3(6):441-79.
88. Darbyshire P, MacDougall C, Schiller W. Multiple methods in qualitative research with children: more insight or just more?. Qualitative Research 2005;5(4):417-36.
89. Dodd M, Janson S, Facione N, Faucett J, Froelicher ES, Humphreys J, et al. Advancing the science of symptom management. Journal of Advanced Nursing 2001;33(5):668-76.
90. Dolgin MJ, Katz ER, McGinty K, Siegel SE. Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 1985;75(3):547-52.
91. Dolgin MJ, Katz ER, Zeltzer LK, Landsverk J. Behavioral distress in pediatric patients with cancer receiving chemotherapy. Pediatrics 1989;84(1):103-10.
92. Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L. Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy 2006;26(9):1221-31.
93. Egger M, Zellweger-Zohner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. The Lancet 1997;350(9074):326-9.
94. Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Supportive Care in Cancer 2005;13(2):112-6.
95. Foot AB, Hayes C. Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis. Archives of Disease in Childhood 1994;71(5):475-80.
96. Gibson F, Aldiss S, Kearney N, Miller M, Maguire R, McCann L, et al. An evaluation of an advanced symptom management system (ASyMS(C)) to monitor and manage chemotherapy related toxicity with young people. Centre for Research Nursing and Allied Health Professions, Great Ormond Street Hospital for Children and Cancer Care. London, 2007.
97. Glass N. UK charity to involve public in decision making for cancer research priorities. The Lancet 2002;360(9344):1487.
98. Hedstrom M, Haglund K, Skolin I, von Essen L. Distressing events for children and adolescents with cancer: child, parent, and nurse perceptions. Journal of Pediatric Oncology Nursing 2003;20(3):120-32.
99. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society. Series A (Statistics in Society) 2009;172(1):137-59.
100. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
101. Hinds PS. Patient-reported outcomes: a desirable specialty standard for oncology or an incomplete measurement approach?. Cancer Nursing 2008;31(4):259-60.
102. Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006;106(4):931-40.
103. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. International Journal of Epidemiology 2002;31(1):115-23.
104. Kremer LCM, Leclercq E, van Dalen EC. Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2014, issue 8. Art. No.: CHILDCA.
105. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg SM, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supportive Care in Cancer 2005;13(2):85-96.
106. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer 1987;60:1651-6.
107. Linder LA. Measuring physical symptoms in children and adolescents with cancer. Cancer Nursing 2005;28(1):16-26.
108. McCorcle R, Cooley M, Shea JA. A User's Manual for the Symptom Distress Scale. Philadelphia: University of Pennsylvania - National Institute of Nursing Research, 1998.
109. Meyer S, Eden T, Kalirai H. Dexamethasone protects against cisplatin-induced activation of the mitochondrial apoptotic pathway in human osteosarcoma cells. Cancer Biology & Therapy 2006;5(8):915-20.
110. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technology Assessment (Winchester, England) 2003;7(41):1-90.
111. Moody K, Meyer M, Mancuso CA, Charlson M, Robbins L. Exploring concerns of children with cancer. Supportive Care in Cancer 2006;14(9):960-6.
112. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61(10):991-6.
113. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
114. Rheingans JI. Pediatric oncology nurses' management of patients' symptoms. Journal of Pediatric Oncology Nursing 2008;25(6):303-11.
115. Richardson J, Smith JE, McCall G, Richardson A, Pilkington K, Kirsch I. Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence. European Journal of Cancer Care 2007;16(5):402-12.
116. Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow R, Warr D, et al. Antiemetics in children receiving chemotherapy. Supportive Care in Cancer 2005;13(2):129-31.
117. Sammons H. Ethical issues of clinical trials in children: a European perspective. Archives of Disease in Childhood 2009;94(6):474-7.
118. Skoup M. A comparison of two dose levels of granisetron in patients receiving high dose cisplatin. European Journal of Cancer 1990;26(Suppl 1):15-9.
119. Smith IE. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. European Journal of Cancer 1990;26(Suppl 1):19-23.
120. Sutton AJ, Higgins JPT. Recent developments in meta-analysis. Statistics in Medicine 2008;27(5):625-50.
121. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. The Lancet 2000;355(9220):2037-40.
122. Tremont-Lukats IW, Bruera E, González-Barboteo J. Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: ]
123. WHO . Make medicines child size. http://www.who.int/childmedicines/en/index.html 6 Dec 2007 (accessed October 2009).
124. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 2005;9(15):1-157, iii-iv-1-157, iii-iv.
125. Williams PD, Schmideskamp J, Ridder EL, Williams AR. Symptom monitoring and dependent care during cancer treatment in children: pilot study. Cancer Nursing 2006;29(3):188-97.
126. Wolfe J, Grier HE, Klar N, Levin SB, Ellenbogen JM, Salem-Schatz S, et al. Symptoms and suffering at the end of life in children with cancer. The New England Journal of Medicine 2000;342(5):326-33.
127. Woodgate RL, Degner LF, Yanofsky R. A different perspective to approaching cancer symptoms in children. Journal of Pain and Symptom Management 2003;26(3):800-17.
128. Woodgate RL. A different way of being: adolescents' experiences with cancer. Cancer Nursing 2005;28(1):8-15.
129. Zeltzer LK, Dolgin MJ, LeBaron S, LeBaron C. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 1991;88(1):34-42.
130. Zhang C, Beckermann B, Kallifatidis G, Liu Z, Rittgen W, Edler L, et al. Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. International Journal of Oncology 2006;29(5):1295-301.
131. Zou GY. One relative risk versus two odds ratios: implications for meta-analyses involving paired and unpaired binary data. Clinical Trials 2007;4(1):25-31.
132. Phillips RS, Gibson F, Gopaul S, Light K, Craig JV, Pizer B. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: ]
133. Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, Pizer B. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: ]